Vertex Pharmaceuticals (VRTX) Assets Average (2010 - 2026)

Vertex Pharmaceuticals' Assets Average history runs 17 years deep, the most recent figure standing at $26.1 billion for Q1 2026.

• On a quarterly basis, Assets Average rose 14.78% year-over-year to $26.1 billion in Q1 2026; TTM through Mar 2026 was $26.1 billion, a 14.78% increase from a year earlier, with the FY2025 full-year figure at $24.1 billion, up 6.44% from the prior year.
• Assets Average rose to $26.1 billion in Q1 2026 per VRTX's latest filing, from $25.3 billion in the prior quarter.
• Across five years, Assets Average topped out at $26.1 billion in Q1 2026 and bottomed at $13.8 billion in Q1 2022.
• The 5-year median for Assets Average is $22.0 billion (2024), against an average of $20.9 billion.
• Across the five-year window, Assets Average surged 34.08% in 2023 and retreated 2.65% in 2025, its largest moves.
• Year by year, Assets Average stood at $17.4 billion in 2022, then gained by 27.54% to $22.2 billion in 2023, then increased by 0.71% to $22.4 billion in 2024, then advanced by 12.8% to $25.3 billion in 2025, then grew by 3.21% to $26.1 billion in 2026.
• Per Business Quant, the three latest VRTX Assets Average figures stand at $26.1 billion (Q1 2026), $25.3 billion (Q4 2025), and $24.4 billion (Q3 2025).